Brokerages Set argenx SE (NASDAQ:ARGX) PT at $630.42

Shares of argenx SE (NASDAQ:ARGX) have been given a consensus rating of “Moderate Buy” by the twenty-three analysts that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $630.42.

Several brokerages have recently commented on ARGX. Piper Sandler raised their price target on argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. boosted their price target on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Barclays upgraded shares of argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and boosted their price objective for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Finally, William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research report on Friday, November 1st.

Institutional Trading of argenx

Institutional investors have recently bought and sold shares of the stock. Advisors Asset Management Inc. increased its stake in argenx by 79.3% during the 1st quarter. Advisors Asset Management Inc. now owns 588 shares of the company’s stock valued at $232,000 after purchasing an additional 260 shares in the last quarter. Silvercrest Asset Management Group LLC raised its stake in argenx by 14.2% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 5,184 shares of the company’s stock worth $2,041,000 after acquiring an additional 646 shares during the last quarter. Wahed Invest LLC lifted its position in argenx by 43.5% during the 1st quarter. Wahed Invest LLC now owns 656 shares of the company’s stock worth $258,000 after acquiring an additional 199 shares during the period. Cetera Advisors LLC purchased a new stake in argenx during the 1st quarter valued at about $419,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of argenx by 1.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 8,445 shares of the company’s stock valued at $3,320,000 after purchasing an additional 128 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Price Performance

Shares of ARGX stock opened at $617.49 on Thursday. The company has a market capitalization of $37.28 billion, a P/E ratio of -701.69 and a beta of 0.61. The company’s 50-day simple moving average is $565.73 and its two-hundred day simple moving average is $498.07. argenx has a one year low of $327.73 and a one year high of $622.32.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter in the prior year, the firm earned ($1.25) earnings per share. On average, research analysts expect that argenx will post 2.2 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.